191 related articles for article (PubMed ID: 12431872)
1. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Behra-Miellet J; Dubreuil L; Jumas-Bilak E
Int J Antimicrob Agents; 2002 Nov; 20(5):366-74. PubMed ID: 12431872
[TBL] [Abstract][Full Text] [Related]
2. Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Speciale A; Musumeci R; Blandino G; Milazzo I; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 2002 Feb; 19(2):111-8. PubMed ID: 11850163
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
Milazzo I; Blandino G; Musumeci R; Nicoletti G; Lo Bue AM; Speciale A
Int J Antimicrob Agents; 2002 Dec; 20(6):451-6. PubMed ID: 12458140
[TBL] [Abstract][Full Text] [Related]
5. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Pong A; Thomson KS; Moland ES; Chartrand SA; Sanders CC
J Antimicrob Chemother; 1999 Nov; 44(5):621-7. PubMed ID: 10552978
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice.
Thadepalli H; Chuah SK; Gollapudi S
Chemotherapy; 2004 Jun; 50(2):76-80. PubMed ID: 15211081
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Edlund C; Sabouri S; Nord CE
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
[TBL] [Abstract][Full Text] [Related]
8. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):305-9. PubMed ID: 10385024
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Blondeau JM; Laskowski R; Bjarnason J; Stewart C
Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
[TBL] [Abstract][Full Text] [Related]
13. [In vitro antibiotic susceptibility to fluoroquinolones].
Wong CA; Galvis V; Tello A; Villareal D; Rey JJ
Arch Soc Esp Oftalmol; 2012 Mar; 87(3):72-8. PubMed ID: 22423655
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Naber KG; Hollauer K; Kirchbauer D; Witte W
Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
[TBL] [Abstract][Full Text] [Related]
15. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli].
Bosnea D; Stadoleanu C; Boswell FJ; Buiuc D
Rev Med Chir Soc Med Nat Iasi; 2000; 104(4):117-22. PubMed ID: 12089939
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Hardy D; Amsterdam D; Mandell LA; Rotstein C
Antimicrob Agents Chemother; 2000 Mar; 44(3):802-5. PubMed ID: 10681365
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
Sobottka I; Neumann S; Laufs R
Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
[TBL] [Abstract][Full Text] [Related]
18. Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria.
Ackermann G; Schaumann R; Pless B; Claros MC; Goldstein EJ; Rodloff AC
Eur J Clin Microbiol Infect Dis; 2000 Mar; 19(3):228-32. PubMed ID: 10795599
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Aktaş Z; Gönüllü N; Salcioğlu M; Bal C; Anğ O
Int J Antimicrob Agents; 2002 Sep; 20(3):196-200. PubMed ID: 12385698
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]